default author photo

Chaosu Hu

Fudan University - Department of Radiation Oncology

China

SCHOLARLY PAPERS

6

DOWNLOADS

496

TOTAL CITATIONS

0

Scholarly Papers (6)

1.

JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Number of pages: 35 Posted: 16 Apr 2021
Prince of Wales Hospital - State Key Laboratory of Oncology in South China, Prince of Wales Hospital - State Key Laboratory of Oncology in South China, Guangzhou Medical University - Department of Radiation Oncology, Fudan University - Department of Radiation Oncology, Huazhong University of Science and Technology - Cancer Center, Guangdong Medical University - Affiliated Hospital, Jiangxi Cancer Hospital - Department of Head and neck radiotherapy, Central South University - Hunan Cancer Hospital, Fujian Provincial Cancer Hospital, Fujian Medical University - Fujian Provincial Hospital, People’s Hospital of Guangxi Zhuang Autonomous Region, Sichuan University - West China Hospital, Central South University - Second Xiangya Hospital, Taichung Veterans General Hospital, Shantou University Medical College - Cancer Hospital, Jiangsu Cancer Hospital, Chang Gung University - Chang Gung Memorial Hospital, National Cancer Centre Singapore, Southern Medical University - Department of Oncology, Chinese Academy of Medical Sciences - Peking Union Medical College, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Sun Yat-sen University (SYSU) - Fifth Affiliated Hospital, Huazhong University of Science and Technology - Department of Oncology, Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital, Fujian Medical University - Union Hospital, Hebei Medical University - Fourth Hospital, Hainan Medical University - Hainan General Hospital, Liuzhou Worker’s Hospital, China Medical University - College of Medicine, National Chiao Tung University - Institute of Clinical Medicine, National Cheng Kung University - Department of Internal Medicine, Tan Tock Seng Hospital, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, TopAlliance Biosciences and Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China
Downloads 179 (422,345)

Abstract:

Loading...

Nasopharyngeal Carcinoma, anti-PD-1 antibody, Toripalimab

2.

Avelumab in Combination with Standard of Care Chemoradiotherapy Versus Chemoradiotherapy Alone in Patients with Locally Advanced SCCHN: A Randomised, Double-Blind, Phase 3 Trial

Number of pages: 28 Posted: 09 Sep 2020
Memorial Sloan Kettering Cancer Center - Department of Radiation Oncology, University of Pittsburgh - Hillman Cancer Center, - Section of Medical Oncology, Harvard University - Department of Medical Oncology, National Cancer Center Hospital East, Groupe d'Oncologie Radiothérapie Tête et Cou (GORTEC), NHS Foundation Trust - Royal Marsden Hospital, National Yang Ming University - Taipei Veterans General Hospital, Changhua Christian Hospital - Department of Radiation Oncology, University of Oklahoma - Stephenson Cancer Center, Instituto Português de Oncologia de Coimbra Francisco Gentil, Semmelweis University - Onkológiai Tanszék, Centre Hospitalier Prive Saint Grégoire - CHP Saint Grégoire, Costa del Sol Hospital - Department of Medical Oncology, Fudan University - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Budgetary Institution of Healthcare of the Omsk Region - Clinical Oncology Dispensary, Pfizer AG, Pfizer, Inc., Pfizer, Inc. and University of California, San Diego (UCSD) - Moores Cancer Center
Downloads 97 (709,832)

Abstract:

Loading...

avelumab, JAVELIN Head and Neck 100, PD-L1, squamous cell carcinoma of the head and neck, immunotherapy, radiation, chemotherapy

3.

Aurora Kinase a Phosphorylates BRCA2 to Promote Cell Sensitivity to PARP Inhibition

Number of pages: 38 Posted: 15 Jul 2022
Fudan University - Department of Radiation Oncology, Fudan University - Cancer Institute, Fudan University - Department of Oncology, Fudan University - Central Laboratory, Fudan University - Central Laboratory, Fudan University - Cancer Institute, Fudan University - Department of Radiation Oncology, Shanghai University of Traditional Chinese Medicine - Center for Reproductive Medicine and Fudan University - Cancer Institute
Downloads 78 (816,709)

Abstract:

Loading...

AURKA, BRCA2, phosphorylation, ubiquitin, PARP inhibitors

4.

A Novel Machine Learning-Derived Radiomic Signature Predictive of Nasopharyngeal Necrosis to Guide Re-Radiotherapy for Recurrent Nasopharyngeal Carcinoma: A Multicentre Study

Number of pages: 34 Posted: 16 Dec 2021
Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Chinese Academy of Sciences (CAS) - CAS Key Laboratory of Molecular Imaging, Chinese Academy of Sciences (CAS) - CAS Key Laboratory of Molecular Imaging, Fudan University - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - Department of Radiology, Sun Yat-sen University (SYSU) - Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University (SYSU) - Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University (SYSU) - Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University (SYSU) - Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Fudan University - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - Zhongshan School of Medicine, Sun Yat-sen University (SYSU) - Zhongshan School of Medicine, Chinese Academy of Sciences (CAS) - CAS Key Laboratory of Molecular Imaging, Chinese Academy of Sciences (CAS) - CAS Key Laboratory of Molecular Imaging, Fudan University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Sun Yat-sen University (SYSU) - Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Beihang University (BUAA) and Sun Yat-sen University (SYSU) - Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy
Downloads 64 (933,592)

Abstract:

Loading...

recurrent nasopharyngeal carcinoma, re-radiotherapy, nasopharyngeal necrosis, radiomics

5.

Multi-Omics-Based Prognostic Prediction for Locally Advanced Hypopharyngeal Cancer Treated with Surgery and Postoperative Chemoradiotherapy: A Dual-Center Study

Number of pages: 22 Posted: 18 Jun 2024
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fudan University - Department of Radiation Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Fudan University - Department of Radiation Oncology, Fudan University - Department of Radiation Oncology and Fudan University - Department of Radiation Oncology
Downloads 42 (1,157,785)

Abstract:

Loading...

Hypopharyngeal cancer, postoperative chemoradiotherapy, Multi-omics, Machine learning

6.

Aurora Kinase a Phosphorylates BRCA2 to Confer Synthetic Lethality to PARP Inhibitors

Number of pages: 55 Posted: 02 Jun 2022
Fudan University - Department of Radiation Oncology, Fudan University - Cancer Institute, Fudan University - Department of Oncology, Fudan University - Central Laboratory, Fudan University - Central Laboratory, Fudan University - Cancer Institute, Fudan University - Department of Radiation Oncology, Shanghai University of Traditional Chinese Medicine - Center for Reproductive Medicine and Fudan University - Cancer Institute
Downloads 36 (1,236,159)

Abstract:

Loading...

AURKA, BRCA2, phosphorylation, ubiquitin, PARP inhibitors